Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 26;11:11023. doi: 10.1038/s41598-021-89389-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Manipulation of PTENP1-AS in BRAFi resistant sublines and evaluation of PTENP1-AS in metastatic melanoma samples. (a) Cell-death analysis by annexin V and propidium iodide staining upon knockdown of PTENP1-AS and vemurafenib treatment (n = 6). (b) Colony formation assays for A375, A375PR1 and A375VR4 cell lines measuring relative absorbance of crystal violet solution stained colonies upon gapmer ASO-induced knockdown of PTENP1-AS co-treated with various concentrations of vemurafenib. (c) Expression data (TCGA) for PTEN and PTENP1-AS from melanoma samples. (d) qRTPCR measuring expression levels of PTENP1-AS in a set of 20 first regional lymph node metastases from stage III melanoma patients. Based on clinical follow up data, the patients were categorized as long- or short-term survivors, > 60 months or ≤ 13 months, respectively. (e) Kaplan–Meier plot showing overall survival for patients with high (n = 12) or low (n = 17) expression levels of PTENP1-AS. Expression levels of PTENP1-AS was measured in first regional lymph node metastases from an independent set of 29 stage III melanoma patients using qRTPCR. The p-value represents a log-rank test.